|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Immtech International Inc. is a pharmaceutical company focused on commercializing a new class of oral drugs to treat infectious diseases. |
|
| Management |
| Eric L. Sorkin, Chairman and Chief Executive Officer; Cecilia Chan, Executive Director and Board Member; Gary C. Parks, Secretary, Treasurer and Chief Financial Officer; Carol Ann Olson, M.D., PhD, Senior Vice President of Pharmaceutical Development and Chief Medical Officer; Norman A. Abood, PhD, Vice President, Discovery Programs; Lawrence A. Potempa, PhD, Vice President; Daniel M. Schmitt, Vice President, Licensing and Commercial Development |
|
|
|
|
| Keywords |
| malaria parasite, oral drugs, pneumonia, malaria, tuberculosis, Diabetes, blood sugar, diabetic, metabolic, insulin, hepatitis |
|
|
|
|
| Description |
|
Immtech International Inc. is a pharmaceutical company focused on commercializing a new class of oral drugs to treat infectious diseases. The Company is committed to developing oral drugs to treat diseases for which there is no cure or to replace existing drugs that have become less effective. Immtech is developing oral drugs to treat infectious diseases such as pneumonia, fungal infections, malaria , tuberculosis, diabetes, hepatitis; and tropical diseases such as African sleeping sickness, and Leishmania. |
|
| Products / Services |
DB289 targeting the Malaria parasite.DB289 for treatment of Trypanosomiasis. Immtech has completed a Phase IIa pilot study using DB289 to treat AIDS patients with PCP, a fungal infection of the lungs that affects immunosuppressed patients (such as those with cancer and HIV).Immtech is developing a joint venture to develop the Diabetes Drug Program. The Program would develop a new oral drug to treat Type II Diabetes.
|
|
| Technology / Differentiation |
| Scientific Consortium scientists have identified several compounds with potential to treat both Candida and Aspergillus, two infections that in the aggregate account for over 90% of the systemic fungal infection drug market. |
|
| Market / Customers |
Global annual sales in 2003 for anti-infective drugs are estimated to be $46 billion.
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
